Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of 4-hydroxy salicylamide in preparing medicament for resisting tumor

A technology of hydroxysalicylanilide and antineoplastic drugs, applied in the application field of 4-hydroxysalicylanilide in the preparation of antineoplastic drugs, capable of solving problems such as lowering blood cholesterol

Active Publication Date: 2013-03-13
ZHEJIANG UNIV +1
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, it has the effect of lowering blood cholesterol

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of 4-hydroxy salicylamide in preparing medicament for resisting tumor
  • Application of 4-hydroxy salicylamide in preparing medicament for resisting tumor
  • Application of 4-hydroxy salicylamide in preparing medicament for resisting tumor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Embodiment 1: the recombinant RR enzyme inhibitory activity of medicine

[0037] 1. Experimental materials

[0038] (1) Main reagents: hydroxyurea (Hydroxyurea, HU, Sigma), 4-hydroxysalicylanilide (Shanghai Titan Chemical Co., Ltd.).

[0039] (2) Main instruments: high performance liquid phase analyzer (Shimadzu LC-10ATVP), liquid scintillation counter (Backman LS6500).

[0040] 2. Experimental method

[0041] (1) Sample preparation for recombinant RR enzyme activity assay

[0042] 1) Prepare the reaction sample: Escherichia coli expressed in vitro the purified recombinant human RR enzyme large subunit M1 (see SEQ ID NO.1 for the sequence) and small subunit M2 protein (see SEQ ID NO.2 for the sequence) (the amount of protein used was RR enzyme activity reaches 65-95%), add double-distilled water to adjust the volume to 80 μl, add 10 μl of different concentrations of test compounds; mix well, and incubate at room temperature for 30-60 minutes;

[0043] 2) Add reaction ...

Embodiment 2

[0052] Embodiment 2: the determination of drug test dosage

[0053] 1. Experimental materials

[0054] (1) Cell line: HepG2.2.15 cells (stably transfected with HBV gene, capable of stably replicating and expressing HBV genome) (gifted by Institute of Infectious Diseases, Zhejiang University).

[0055] (2) Main reagents: DMEM medium (Gibco, USA), fetal bovine serum (Gibco, USA), hydroxyurea (Hydroxyurea, HU, Sigma), 4-hydroxy salicylanilide (Shanghai Titan Chemical Co., Ltd.), pull Mivudine (Lamivudine, 3-TC, Tokyo Ninsei Industry Co., Ltd., Japan); Cell Counting Kit-8 kit (CCK8, Dojin Chemical Research Institute, Japan Co., Ltd.).

[0056] (3) Main instruments: carbon dioxide incubator (Thermo Forma, USA), automatic microplate reader (Bio-TEK, Elx800).

[0057] 2. Experimental method

[0058] (1) Cell culture:

[0059] Cells were cultured in DMEM high-glucose medium (DMEM medium supplemented with 10% fetal bovine serum, pH 7.2), added with 400 μg / ml G418, 2 mmol / L glutamin...

Embodiment 3

[0068] Example 3: Drugs inhibit the expression level of HBsAg in the culture supernatant of HepG2.2.15 cells

[0069] 1. Experimental materials

[0070] (1) Main reagents: HBsAg detection ELISA kit (Shanghai Yanji Biotechnology Co., Ltd.).

[0071] (2) Main instrument: automatic microplate reader (Bio-TEK, Elx800).

[0072] 2. Experimental method

[0073] HepG2.2.15 cells (5×10 4 unit / mL) CO 2 After culturing in the incubator for 24 hours, the cells adhered to the wall and grew well, and the culture medium was removed. According to the results of the cytotoxicity test, the cell culture medium containing different concentrations of drugs without G418 was added, and each concentration was set for 3 replicates. Cells in complete medium as normal control, 5% CO 2 , Culture at 37°C. After 48h, 72h, and 96h of continuous culture, the supernatant of each sample was drawn and placed in a 1.5mL sterilized centrifuge tube, centrifuged at 1000rcf for 10min to take the supernatant, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides novel application of 4-hydroxy salicylamide in the field of pharmacy. The compound is an inhibitor of ribonucleotide reductase (RR), and can achieve the aims of inhibiting replication of HBV and treating hepatitis, in particular the hepatitis B by inhibiting activity of RR enzyme to block synthesis of dNTPs (deoxynucleotide triphosphates) required by hepatitis B virus (HBV) replication, achieve the aim of preventing and treating liver cancer by inhibiting the activity of RR of liver cancer cells, including the RR activity activated by HBV to inhibit proliferation of liver cancer cells, and achieve the aim of treating various tumors by inhibiting the RR. The 4-hydroxy salicylamide can be used for preventing and treating hepatitis B, liver cancer, oropharyngeal epithelioma, colorectal cancer, ovarian cancer, non-small cell lung cancer, chronic myeloid leukemia and other tumors, and has important application prospect.

Description

(1) Technical field [0001] The present invention relates to the application of 4-hydroxy salicylanilide in the preparation of drugs targeting ribonucleotide reductase (Ribonucleotide reductase, RR), especially the application of 4-hydroxy salicylanilide in the preparation of drugs targeting RR enzymes Drugs for preventing and treating hepatitis and application in antineoplastic drugs. (2) Background technology [0002] Chronic hepatitis is one of the serious infectious diseases threatening human health worldwide. About more than 2 billion people in the world have been infected with hepatitis B virus (Hepatitis B Virus, HBV), and the number of deaths due to HBV infection reaches 1 million every year. HBV infection is not only an important biological factor causing chronic hepatitis B, but also primary liver cancer. China, Southeast Asia, and Africa are high-incidence areas of HBV infection, and the incidence of primary liver cancer is significantly higher than that in low-i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/609A61P1/16A61P35/00A61P35/02A61P31/20
Inventor 邵吉民朱维良徐志建陈新焕刘霞
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com